DK2200588T3 - Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf - Google Patents

Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK2200588T3
DK2200588T3 DK08832858.8T DK08832858T DK2200588T3 DK 2200588 T3 DK2200588 T3 DK 2200588T3 DK 08832858 T DK08832858 T DK 08832858T DK 2200588 T3 DK2200588 T3 DK 2200588T3
Authority
DK
Denmark
Prior art keywords
lipofile
production
compositions concerning
relations
active
Prior art date
Application number
DK08832858.8T
Other languages
English (en)
Inventor
Krayz Galia Temtsin
Maryana Averbuch
Larisa Gitis
Ilya Zelkind
Original Assignee
Solubest Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340343&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2200588(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solubest Ltd filed Critical Solubest Ltd
Application granted granted Critical
Publication of DK2200588T3 publication Critical patent/DK2200588T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK08832858.8T 2007-09-25 2008-09-25 Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf DK2200588T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97504507P 2007-09-25 2007-09-25
US97506607P 2007-09-25 2007-09-25
PCT/IL2008/001294 WO2009040818A1 (en) 2007-09-25 2008-09-25 Compositions comprising lipophilic active compounds and method for their preparation

Publications (1)

Publication Number Publication Date
DK2200588T3 true DK2200588T3 (da) 2019-07-01

Family

ID=40340343

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08832858.8T DK2200588T3 (da) 2007-09-25 2008-09-25 Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf

Country Status (12)

Country Link
US (2) US9254268B2 (da)
EP (2) EP2200588B1 (da)
AU (1) AU2008303129B2 (da)
CA (1) CA2700426C (da)
DK (1) DK2200588T3 (da)
ES (1) ES2731881T3 (da)
HR (1) HRP20191104T1 (da)
HU (1) HUE043897T2 (da)
IL (1) IL204711A0 (da)
PL (1) PL2200588T3 (da)
SI (1) SI2200588T1 (da)
WO (1) WO2009040818A1 (da)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008015018A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
JP2012527491A (ja) * 2009-05-27 2012-11-08 サムヤン バイオファーマシューティカルズ コーポレイション 生体利用率が向上した難溶性薬物含有微粒球およびその製造方法
CN101637473B (zh) * 2009-06-19 2011-08-17 山东大学 一种含雷洛昔芬的药物配伍组合及其应用
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
PT2501234T (pt) 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
GR1007244B (el) * 2010-01-14 2011-04-21 Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδος, Εμπορια Φαρμακων, Ποσιμα διαλυματα φλουκοναζολης
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
KR101907411B1 (ko) 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
JP2013530931A (ja) * 2010-04-23 2013-08-01 ラボファーマ インコーポレイテッド 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
GB201007290D0 (en) * 2010-04-30 2010-06-16 R5 Pharmaceuticals Ltd Pharmaceutical powder compositions
GB201008043D0 (en) * 2010-05-14 2010-06-30 Unilever Plc Compositions
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
CN102008435B (zh) * 2010-08-25 2012-01-11 齐鲁动物保健品有限公司 一种禽用癸氧喹酯口服混悬液及其制备方法
AU2011297045B2 (en) * 2010-09-02 2014-12-18 Nippon Kayaku Kabushiki Kaisha Process for producing drug-block-copolymer composite and pharmaceutical product containing same
LT3023102T (lt) 2010-11-08 2018-09-25 Albireo Ab Ibat inhibitoriai, skirti kepenų ligų gydymui
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
EP2679230A4 (en) * 2011-02-25 2014-07-23 Nanocare Technologies Inc PHARMACEUTICAL FORMULATION WITH JASMONATE FAMILY COMPOUNDS
EP2701684B1 (en) 2011-04-28 2017-06-14 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2012174121A2 (en) * 2011-06-13 2012-12-20 The University Of Kansas Decoquinate prodrugs
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN104203222A (zh) 2011-09-16 2014-12-10 纳米整理技术公司 茉莉酮酸酯化合物的组合物和使用方法
JP6261512B2 (ja) * 2011-11-16 2018-01-17 デューク ユニバーシティ 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
CN102579395B (zh) * 2012-03-30 2013-10-30 江苏万禾制药有限公司 一种硫辛酸胶囊及其制备工艺和用途
US20150057321A1 (en) 2012-04-04 2015-02-26 Intervet Inc. Soft chewable pharmaceutical products
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
CN103539967B (zh) * 2012-07-16 2017-10-20 上海市肿瘤研究所 核壳结构聚合物/纳米金复合纳米材料及其制备方法和应用
WO2014042598A1 (en) * 2012-09-17 2014-03-20 National University Of Singapore Drug therapy for cancer, including multiple myeloma
US20140127385A1 (en) * 2012-11-04 2014-05-08 Ingredient Innovations International Stable Aqueous Dispersions of Poorly Soluble Crystalline Nutrients
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
DE102012113098A1 (de) * 2012-12-27 2014-07-03 Hennig Arzneimittel Gmbh & Co. Kg Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
BR102013021210B1 (pt) * 2013-01-25 2015-12-01 Fundação Universidade Fed De São Carlos processo de obtenção de nanopartículas biopoliméricas contendo óleo e extratos de azadirachta indica a. juss (neem), nanopartículas biopoliméricas e micropartículas em pó
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
BR112015021002B8 (pt) 2013-03-15 2023-03-28 Mallinckrodt Llc Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
TWI740136B (zh) 2013-03-15 2021-09-21 愛爾蘭商托尼克製藥控股有限公司 環苯扎林鹽酸鹽及阿密替林鹽酸鹽之共晶調配物
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9511341B2 (en) 2013-08-30 2016-12-06 Sunny Pharmtech Inc. Method for preparing acetazolamide sodium powder
HUE048498T2 (hu) 2013-09-16 2020-07-28 Astrazeneca Ab Terápiás polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9642811B2 (en) 2014-03-26 2017-05-09 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN103877064B (zh) * 2014-04-11 2016-04-27 白玲强 一种非诺贝特胶囊剂及其制备工艺
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
CA2953396C (en) 2014-07-03 2022-11-08 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
CN104146968B (zh) * 2014-07-23 2017-01-18 国药集团容生制药有限公司 注射用甲泼尼龙琥珀酸钠及其制备方法
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
CN104188975A (zh) * 2014-08-20 2014-12-10 冷敏 一种治疗压疮的西药组合物、乳膏及其乳膏的制备方法
JP6614724B2 (ja) * 2014-09-18 2019-12-04 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
WO2016044733A1 (en) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Methods of preparing extrudates
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
MX2017008655A (es) 2014-12-31 2018-04-10 Nanocare Tech Inc Derivados de jasmonato y composiciones de los mismos.
WO2016145132A1 (en) * 2015-03-12 2016-09-15 Fmc Corporation Solid dispersions
BR112017025739A2 (pt) * 2015-05-29 2018-08-07 Sun Pharmaceutical Ind Ltd composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11291630B2 (en) 2015-09-16 2022-04-05 Centre National De La Recherche Scientifique (Cnrs) Gelling compositions for treating malignant tumours and/or preventing tumour recurrence
WO2017049083A2 (en) * 2015-09-16 2017-03-23 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
CN106631869A (zh) * 2015-12-06 2017-05-10 宁夏际华环境安全科技有限公司 一种二硝托胺脂生产工艺
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10441604B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109922801B (zh) 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
CA3038989A1 (en) 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
KR102658256B1 (ko) 2017-03-15 2024-04-16 디에프비 소리아, 엘엘씨 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
US10555899B2 (en) 2017-06-05 2020-02-11 Piedmont Animal Health, Llc Long-acting non-aqueous injectable formulations and use thereof
EP3658123A4 (en) 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH HIGH ACTIVE INGREDIENT LOAD
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CN107854424A (zh) * 2017-10-30 2018-03-30 沈小玲 一种阿奇霉素眼用原位凝胶及其制备方法
WO2019086425A1 (en) * 2017-11-03 2019-05-09 Dsm Ip Assets B.V. New delivery system
AU2018383098A1 (en) 2017-12-11 2020-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CA3096101A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
SG11202012170PA (en) 2018-06-20 2021-01-28 Albireo Ab Pharmaceutical formulation of odevixibat
CN112752570A (zh) 2018-08-03 2021-05-04 Ptc医疗公司 生物可利用口服剂型
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
CN109674767A (zh) * 2019-01-18 2019-04-26 安徽瑞达健康产业有限公司 一种含有番茄红素的微丸及其制备方法
EP3884930A1 (en) * 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
EP3943071A1 (de) 2020-03-31 2022-01-26 Zurab Durmischchanowitch Khinikadze Zusammensetzung, enthaltend natürliche lipophile verbindungen, verwendung der zusammensetzung und verfahren zur herstellung der zusammensetzung
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
CN112190567B (zh) * 2020-11-09 2022-03-11 山东华辰制药有限公司 一种伊维菌素缓释微球的制备方法及应用
CN112999196B (zh) * 2021-03-03 2023-04-28 西安医学院 用于长效稳定释放的吗替麦考酚酯纳米制剂及其制备方法
CN113133989B (zh) * 2021-03-09 2023-04-25 西安医学院 一种用于抗结核药物利福平的长效制剂及制备方法
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone
CN115531306B (zh) * 2022-05-12 2024-03-26 南京锐志生物医药有限公司 一种注射用左奥硝唑衍生物乳状制剂及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0580860T4 (da) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
CA2111851C (en) 1991-06-21 2002-02-26 Wolfgang Grell (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
ES2199289T3 (es) 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
WO1997006787A2 (en) 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CA2261456A1 (en) 1998-02-23 1999-08-23 F. Hoffmann-La Roche Ag Preparation of a finely divided pulverous carotenoid preparation
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6730322B1 (en) * 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
MXPA01012225A (es) 1999-05-28 2002-08-12 Abbott Lab Formulaciones novedosas que comprenden agentes reguladores de lipido.
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE60129573T2 (de) 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
US8071133B2 (en) 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
IL160957A0 (en) * 2001-09-28 2004-08-31 Solubest Ltd Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
CA2488499C (en) 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
EP1521571A1 (en) 2002-07-04 2005-04-13 Janssen Pharmaceutica N.V. Solid dispersion comprising two different polymer matrixes
WO2004069138A2 (en) 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
PT1663217E (pt) 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
MXPA06003813A (es) 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US8974823B2 (en) 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
EP1701703B1 (en) 2003-12-31 2011-03-09 Bend Research, Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006060817A1 (en) 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
EP1835889A1 (en) 2004-12-15 2007-09-26 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
AU2005326168A1 (en) 2004-12-21 2006-08-03 Baxter Healthcare S.A. (polyalkoxy)sulfonate surface modifiers
CA2600407A1 (en) 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Fibrate compositions containing a surfactant mixture of peg-600 and poloxamer 407
CN101257894A (zh) 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
WO2007141806A1 (en) 2006-06-02 2007-12-13 Jubilant Organosys Ltd Pharmaceutical formulations comprising oxcarbazepine and methods thereof
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra

Also Published As

Publication number Publication date
EP2200588A1 (en) 2010-06-30
AU2008303129B2 (en) 2013-08-01
ES2731881T3 (es) 2019-11-19
US9254268B2 (en) 2016-02-09
EP2601935A1 (en) 2013-06-12
HUE043897T2 (hu) 2019-09-30
HRP20191104T1 (hr) 2019-09-20
US20160220505A1 (en) 2016-08-04
SI2200588T1 (sl) 2019-08-30
WO2009040818A1 (en) 2009-04-02
EP2200588B1 (en) 2019-03-20
WO2009040818A9 (en) 2010-05-20
AU2008303129A1 (en) 2009-04-02
CA2700426C (en) 2017-10-31
PL2200588T3 (pl) 2019-09-30
US20090098200A1 (en) 2009-04-16
IL204711A0 (en) 2017-01-31
CA2700426A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
DK2200588T3 (da) Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2297385T3 (da) Polymere sammensætninger, som omfatter polymælkesyre, og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0906473A2 (pt) Certas entidades químicas, composições e métodos
DK2240155T3 (da) Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK3530740T3 (da) Thraustochytrider, fedtsyresammensætninger og fremgangsmåder til fremstilling deraf og anvendelser deraf
DK2373716T3 (da) Cyclohexanpolycarboxylsyrederivater som blødgørere til klæbe- og tætningsmasse
BRPI0919575A2 (pt) método, e, composição
DK2245032T3 (da) Folater, sammensætninger og anvendelser deraf
BRPI0809573A2 (pt) composição, e, método
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2019090T3 (da) Substitueret beta-phenyl-alfa-hydroxypropansyre, fremgangsmåde til syntese og anvendelse deraf
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK3812360T3 (da) Monochlortrifluorpropen forbindelser og sammensætninger og metoder, der anvender dem
BRPI0920741A2 (pt) diamante policristalino, compactado de diamante policristalino, método de fabricação do mesmo, e suas diversas aplicações.
DK3136030T3 (da) Fremgangsmåde til lyofilisering
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2094842T3 (da) Nye laccaser, sammensætninger og anvendelsesfremgangsmåder
BRPI0823277A2 (pt) Composição, e , método
DK2408337T3 (da) Pude, kit og fremgangsmåde til fremstilling heraf
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
BRPI0906556A2 (pt) Composto, e, composição farmacêutica